AMENDMENT

Kindly amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents as follows:

IN THE CLAIMS:

Kindly amend the claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents as follows:

1. (Currently Amended) A vaccine composition to induce a protective immune response against West Nile virus (WNV) in an animal susceptible to WNV comprising a vector comprising a recombinant avipox virus ~~or DNA plasmid~~ that encodes and expresses *in vivo* in the animal ~~WNV E; WNV prM and E; WNV M and E; WNV prM, WNV M and E, WNV polyprotein prM-E, WNV polyprotein M-E, or~~ WNV polyprotein prM-M-E.

2-4. (Cancelled)

5. (Currently Amended) The vaccine composition of claim 1 [[4]] wherein the recombinant avipox virus is a ~~cannarypox~~ canarypox or fowlpox virus.

6. (Currently Amended) The vaccine composition of claim 5 wherein the canarypox virus is ALVAC and the fowlpox virus is TROVAC.

7-9. (Cancelled)

10. (Previously Presented) The vaccine composition of claim 1 wherein the nucleic acid molecule comprises nucleotides 466-741, 742-966 and 967-2469 of GenBank AF196835 (SEQ ID NO: 66) encoding WNV prM, M and E, respectively.

11. (Previously Presented) The vaccine composition of claim 1 wherein the nucleic acid molecule comprises nucleotides 466-2469 of GenBank AF196835 (SEQ ID NO: 66) encoding WN protein prM-M-E.

12. (Previously Presented) The vaccine composition of claim 1 wherein the nucleic acid molecule comprises nucleotides 421-2469 of GenBank AF196835 (SEQ ID NO: 66) encoding WN protein prM-M-E and the signal peptide of prM.

13. (Previously Presented) The vaccine composition of claim 1, further comprising an adjuvant.

14. (Previously Presented) The vaccine composition according to claim 10, wherein the adjuvant is a carbomer.

15. (Previously Presented) The vaccine composition of claim 1 further comprising an antigen or immunogen or epitope thereof of a pathogen other than WNV of the animal, or a vector that contains and expresses *in vivo* in the animal a nucleic acid molecule encoding the antigen, immunogen or epitope thereof, or an inactivated or attenuated pathogen other than WNV of the animal.

16. (Previously Presented) The vaccine composition of claim 1, wherein the animal is a cat or a horse.

17. (Previously Presented) A method for inducing a protective immune response against WNV in an animal comprising administering to the animal the vaccine composition according to claim 1.

18. (Previously Presented) A method for inducing a protective response against WNV in an animal comprising administering to the animal the vaccine composition according to claim 1, wherein the composition additionally comprises an adjuvant.

19. (Previously Presented) The method according to claim 18 wherein the adjuvant comprises a carbomer adjuvant.

20. (Previously Presented) A method for inducing a protective immune response against WNV and a second pathogen in an animal comprising administering to the animal the vaccine composition according to 15.

21. (Previously Presented) A method for inducing a protective immune response against WNV in an animal comprising administering to the animal (a) the vaccine composition according to claim 1, and (b) a WNV isolated antigen, immunogen or epitope thereof, wherein (a) is administered prior to (b) in a prime-boost regimen, or (b) is administered prior to (a) in a prime-boost regimen, or (a) and (b) are administered together, either sequentially or in admixture.

22. (Original) The method of any of claims 17, 20 or 21, wherein the animal is a cat or a horse.

23-29. (Cancelled)

30. (Currently Amended) A vaccine composition to induce a protective immune response against West Nile virus (WNV) in an animal susceptible to WNV comprising a vector

comprising a recombinant canarypox virus ~~or DNA plasmid~~ that encodes and expresses *in vivo* in the animal WNV polyprotein prM-M-E.

31. (New) The vaccine composition of claim 6, wherein the recombinant ALVAC virus is vCP2017.